Skip to main content

Perspectives

Guiding Employer Management of Specialty Drugs

Cheryl Larson, F. Randy Vogenberg, PhD, FASHP

Healthcare Reform After SCOTUS: Hard Decisions Needed to Avoid Health Sector Meltdown

Joseph R. Antos, PhD

Implications of the Employer Mandate Delay on the Healthcare Marketplace

Kip Piper, MA, FACHE, F. Randy Vogenberg, PhD, FASHP

Regulatory, Perspectives

Implications of the New Political Realities on Healthcare Reform

Increasing Focus on Value Related to Cancer Drugs: A Payer Perspective

Matthew Mitchell, PharmD, MBA, FAMCP

Interesting Times Ahead: Payers’ Innovation in the Era of Healthcare Reform

Albert Tzeel, MD, MHSA, CPE, FAAPL

Key Strategic Trends that Impact Healthcare Decision-Making and Stakeholder Roles in the New Marketplace

John Santilli, MBA, F. Randy Vogenberg, PhD, FASHP

Leading Population Health Efforts: The Power of Vowels

Richard G. Stefanacci, DO, MGH, MBA, AGSF, Anindita Banerjee, BSc, MBA

Richard G. Stefanacci, DO, MGH, MBA, AGSF; Anindita Banerjee, BSc, MBA

Medication Optimization: Integration of Comprehensive Medication Management into Practice

M. Shawn McFarland, PharmD; Shannon W. Finks, PharmD; Lisa Smith, MD; Marcia L. Buck, PharmD; Heather Ourth, PharmD; Amanda Brummel, PharmD; for the Get the Medications Right Institute

Clinical, Perspectives

Modeling Costs and Outcomes Associated with a Treatment Algorithm for Problem Bleeding Episodes in Patients with Severe Hemophilia A and High-Titer Inhibitors

Patrick Bonnet, PharmD, Alessandro Gringeri, MD, Edward Gomperts, MD, Cindy Anne Leissinger, MD, Roseline d’Oiron, MD, Jerome Teitel, MD, Guy Young, MD, Meg Franklin, PharmD, PhD, Bruce Ewenstein, MD, Erik Berntorp, MD, PhD

Stakeholder Perspective

Potential Cost-Savings Using a Treatment Algorithm for Problem Bleeding Episodes in Patients with Hemophilia and Inhibitors

by Hetty A. Lima, RPh, FASHP

1
2
3
4
5

Page 3 of 5
Results 21 - 30 of 48